



January 2025



**\$3,500,000**

Private Placement

Co-Placement Agent



For more information please contact :

### Investment Banking

Gaurav Verma  
Co-Head, Investment Banking  
Direct: +1 (929) 528-0912  
gverma@dboralcapital.com

Stephanie Hu  
Co-Head, Investment Banking  
Direct: +1 (929) 586-0272  
shu@dboralcapital.com

Dr. David Sans  
Senior Managing Director  
Direct: +1 (929) 586-1338  
dsans@dboralcapital.com

### Equity Capital Markets

Philip Wiederlight  
Chief Operating Officer  
Direct: +1 (929) 625-1539  
pwiederlight@dboralcapital.com

Mark Iorio  
Director, Equity Capital Markets  
Direct: +1 (929) 528-0913  
miorio@dboralcapital.com

## D. Boral Capital Served as Co-Placement Agent to Kairos Pharma, Ltd. In connection with its \$3.5 Million Private Placement

### Transaction Information

LOS ANGELES, CA – Kairos Pharma, Ltd. (NYSE American: KAPA), a pharmaceutical company specializing in the development of medical preparations, announced today that it has entered into a securities purchase agreement with accredited investors to raise \$3.5 million in gross proceeds before fees and expenses. The funds are being raised through a private investment in public equity (PIPE) transaction. Under the terms of the agreement, Kairos Pharma will issue 2,500,000 common units at \$1.40 each, with each unit consisting of one common share and one warrant to purchase one and a half additional common shares. The pre-funded warrants are exercisable at \$0.001 per share and can be exercised immediately, while the common warrants have an exercise price of \$1.40 per share and will become exercisable six months after issuance. The common warrants will expire five and a half years from the date of issuance.

### About Kairos Pharma, Ltd.

Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV105, is an antibody that targets CD105-a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. For more information, visit the company's website at <https://kairospharma.com/>

### About D. Boral Capital

D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, UAE, and Latin America.

D. Boral Capital is a leader on Wall Street, having aggregated over \$23 billion in capital across approximately 300 transactions through various product types.